<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Photocure — News on 6ix</title>
<link>https://6ix.com/company/photocure</link>
<description>Latest news and press releases for Photocure on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 07:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/photocure" rel="self" type="application/rss+xml" />
<item>
<title>Photocure ASA: Update on Regulatory Classification for OAY Equipment</title>
<link>https://6ix.com/company/photocure/news/photocure-asa-update-on-regulatory-classification-for-oay-equipment</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-asa-update-on-regulatory-classification-for-oay-equipment</guid>
<pubDate>Mon, 13 Apr 2026 07:30:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today announced that the U.S. Food and Drug Administration (FDA) has communicated to Photocure that it plans to issue a proposed order to reclassify diagnostic endoscopic light source systems (FDA Product Code OAY) under its own initiative per Section 513(f)(3) of the Federal Food, Drug, and Cosmetic Act.</description>
</item>
<item>
<title>Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway</title>
<link>https://6ix.com/company/photocure/news/photocure-trials-in-progress-presented-at-the-european-association-of-urology-eau-2026-congress-aim-to-enable-a-more-personalized-bladder-cancer-care-pathway-2</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-trials-in-progress-presented-at-the-european-association-of-urology-eau-2026-congress-aim-to-enable-a-more-personalized-bladder-cancer-care-pathway-2</guid>
<pubDate>Mon, 16 Mar 2026 16:49:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate different stages of the diagnostic pathway, addressing data gaps to improve individual patient care and outcomes.</description>
</item>
<item>
<title>Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe</title>
<link>https://6ix.com/company/photocure/news/photocure-partner-asieris-announces-that-ema-has-accepted-marketing-authorization-application-for-cevira-in-europe</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-partner-asieris-announces-that-ema-has-accepted-marketing-authorization-application-for-cevira-in-europe</guid>
<pubDate>Fri, 27 Feb 2026 10:03:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its marketing authorization application (MAA) for Cevira® (APL-1702) for the treatment of high-grade squamous intraepithelial lesions (HSIL) has been accepted by the European Medicines Agency (EMA).</description>
</item>
<item>
<title>Photocure ASA: Results for the fourth quarter of 2025</title>
<link>https://6ix.com/company/photocure/news/photocure-asa-results-for-the-fourth-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-asa-results-for-the-fourth-quarter-of-2025</guid>
<pubDate>Wed, 18 Feb 2026 06:44:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a commercial EBITDA of NOK 8.4 million (Q4 2024: NOK 3.9 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and continued operating leverage flow-through in its core Hexvix®/Cysview® commercial business.</description>
</item>
<item>
<title>The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison</title>
<link>https://6ix.com/company/photocure/news/the-impact-of-avoiding-recurrence-new-bravo-study-abstract-at-suo-2025-demonstrates-cost-neutrality-in-blue-light-versus-white-light-cystoscopy-comparison</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/the-impact-of-avoiding-recurrence-new-bravo-study-abstract-at-suo-2025-demonstrates-cost-neutrality-in-blue-light-versus-white-light-cystoscopy-comparison</guid>
<pubDate>Mon, 08 Dec 2025 07:30:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 Annual Meeting (SUO) December 2-5, 2025, in Phoenix, AZ. The abstract 'COSTS OF CARE AND ONCOLOGIC OUTCOMES ASSOCIATED WITH BLUE LIGHT CYSTOSCOPY IN AN EQUAL ACCESS SETTING: RESULTS FROM THE BRAVO STUDY' compares costs in non-muscle-invasive bladder cancer (NMIBC) care, incurred by white light cystoscopy (WLC) versus blue li</description>
</item>
<item>
<title>New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management</title>
<link>https://6ix.com/company/photocure/news/new-budget-impact-model-study-in-4-european-countries-concludes-that-blc-use-offers-a-clinically-meaningful-and-economically-rational-approach-to-nmibc-management</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/new-budget-impact-model-study-in-4-european-countries-concludes-that-blc-use-offers-a-clinically-meaningful-and-economically-rational-approach-to-nmibc-management</guid>
<pubDate>Wed, 19 Nov 2025 07:34:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): The influence of differing European health care payment systems on the potential financial impact of adoption" in the Journal of Medical Economics this week. The research objective was to compare the economic implications of blue light cystoscopy (BLC®) adoption in line with national guide</description>
</item>
<item>
<title>Photocure ASA: Results for the third quarter of 2025</title>
<link>https://6ix.com/company/photocure/news/photocure-asa-results-for-the-third-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-asa-results-for-the-third-quarter-of-2025</guid>
<pubDate>Wed, 29 Oct 2025 06:27:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 million) for the company. Looking ahead, Photocure expects product revenue growth in the range of 8% to 10% on a constant currency basis (compared to 7 to 11% previously) and an EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued</description>
</item>
<item>
<title>Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy</title>
<link>https://6ix.com/company/photocure/news/photocure-and-intelligent-scopes-corporation-partner-on-development-of-ai-for-blue-light-cystoscopy</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-and-intelligent-scopes-corporation-partner-on-development-of-ai-for-blue-light-cystoscopy</guid>
<pubDate>Wed, 15 Oct 2025 15:25:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with blue light cystoscopy (BLC®). Initial testing shows promising performance results.</description>
</item>
<item>
<title>Photocure ASA: Results for the second quarter of 2025</title>
<link>https://6ix.com/company/photocure/news/photocure-asa-results-for-the-second-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-asa-results-for-the-second-quarter-of-2025</guid>
<pubDate>Wed, 30 Jul 2025 05:10:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and an EBITDA of NOK 14.8 million (Q2 2024: NOK 27.8 million, including a milestone payment of NOK 21.6 million) for the company. Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating le</description>
</item>
<item>
<title>Photocure ASA: Results for the first quarter of 2025</title>
<link>https://6ix.com/company/photocure/news/photocure-asa-results-for-the-first-quarter-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-asa-results-for-the-first-quarter-of-2025</guid>
<pubDate>Thu, 08 May 2025 05:08:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million), and an EBITDA of NOK 1.8 million (7.9) for the company. Photocure expects product revenue growth in the range of 7% to 11% and YoY EBITDA improvement in 2025. While the Company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in mileston</description>
</item>
<item>
<title>Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making</title>
<link>https://6ix.com/company/photocure/news/bladder-cancer-presentations-at-aua2025-blue-light-cystoscopy-improves-risk-stratification-and-informed-decision-making</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/bladder-cancer-presentations-at-aua2025-blue-light-cystoscopy-improves-risk-stratification-and-informed-decision-making</guid>
<pubDate>Tue, 29 Apr 2025 06:24:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk stratification and therefore the ability of the BLC procedure to help urologists and patients make well-informed decisions. The American Urological Association Annual Congress 2025 was held April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.</description>
</item>
<item>
<title>Photocure appoints Jane Healy as Vice President and General Manager EMEA</title>
<link>https://6ix.com/company/photocure/news/photocure-appoints-jane-healy-as-vice-president-and-general-manager-emea</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-appoints-jane-healy-as-vice-president-and-general-manager-emea</guid>
<pubDate>Wed, 26 Mar 2025 07:23:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA.</description>
</item>
<item>
<title>Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer</title>
<link>https://6ix.com/company/photocure/news/clinical-data-presentations-at-the-european-association-of-urology-eau-2025-congress-highlight-the-benefits-of-using-blue-light-cystoscopy-in-bladder-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/clinical-data-presentations-at-the-european-association-of-urology-eau-2025-congress-highlight-the-benefits-of-using-blue-light-cystoscopy-in-bladder-cancer</guid>
<pubDate>Mon, 24 Mar 2025 17:23:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in Madrid, Spain, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on recurrence risk and ability to help urologists make the best bladder cancer management choices for their patients.</description>
</item>
<item>
<title>New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence</title>
<link>https://6ix.com/company/photocure/news/new-bravo-study-publication-reinforces-clinical-benefits-of-blc-in-reducing-risk-of-bladder-cancer-recurrence</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/new-bravo-study-publication-reinforces-clinical-benefits-of-blc-in-reducing-risk-of-bladder-cancer-recurrence</guid>
<pubDate>Fri, 14 Mar 2025 07:17:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess if blue light cystoscopy (BLC®) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurr</description>
</item>
<item>
<title>Photocure ASA: Results for the fourth quarter of 2024</title>
<link>https://6ix.com/company/photocure/news/photocure-asa-results-for-the-fourth-quarter-of-2024</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/photocure-asa-results-for-the-fourth-quarter-of-2024</guid>
<pubDate>Wed, 19 Feb 2025 07:30:00 GMT</pubDate>
<description>Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK 29.9 million). Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in mile</description>
</item>
<item>
<title>News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared</title>
<link>https://6ix.com/company/photocure/news/news-on-richard-wolfphotocure-collaboration-interim-flexible-blc-solution-available-in-countries-where-system-blue-and-richard-wolf-reusable-flexible-cystoscopes-are-cleared</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/news-on-richard-wolfphotocure-collaboration-interim-flexible-blc-solution-available-in-countries-where-system-blue-and-richard-wolf-reusable-flexible-cystoscopes-are-cleared</guid>
<pubDate>Mon, 17 Feb 2025 17:56:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces an update regarding its ongoing collaboration with Richard Wolf to develop a high-definition flexible blue light cystoscope for global commercialization. The development process for an optimized solution is progressing on plan, with an interim solution now available to centers in all countries where System blue and other components are cleared.</description>
</item>
<item>
<title>Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025</title>
<link>https://6ix.com/company/photocure/news/bladder-cancer-upstaging-and-risk-mitigation-with-blue-light-cystoscopy-in-nmibc-featured-at-asco-gu-2025</link>
<guid isPermaLink="true">https://6ix.com/company/photocure/news/bladder-cancer-upstaging-and-risk-mitigation-with-blue-light-cystoscopy-in-nmibc-featured-at-asco-gu-2025</guid>
<pubDate>Mon, 17 Feb 2025 06:54:00 GMT</pubDate>
<description>Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview,</description>
</item>
</channel>
</rss>